Combinatorial drug therapy for cancer in the post-genomic era

By B. Al-Lazikani, U. Banerji, P. Workman. Nature Biotechnology, 2012

1,002 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Combining genomic and network characteristics for extended capability in predicting synergistic drugs for cancer (2015, positive): “In the clinic, treatment with anticancer drugs through monotherapy has been frequently associated with acquired resistance and side effects for a couple of years, whereas combinational therapy has been widely explored as a better alternative 1 .”
Synergistic drug combinations for cancer identified in a CRISPR screen for pairwise genetic interactions (2017, neutral): “mU6-driven (700 sgRNAs) (2) Lentiviral infection + puromycin selection in Cas9-K562 cells (3) Selection in bioreactors”
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset (2015, positive): “Combination treatments may mitigate the development of the drug resistance often observed with single-treatment therapies (42), yet principled methods to identify effective combinations have yet to be defined.”